spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  minimal residual disease 

 HSMN NewsFeed - 20 Oct 2025
GRAIL, Inc. Announces $325.0 Million Private Placement Financing
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Feb 2024
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 25 Sep 2023
Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach
Diagnostics Venture Capital
 HSMN NewsFeed - 16 Nov 2022
Haystack Oncology Launches with $56 Million in Series A Financing to Accelerate Adoption of Post-Op Cancer Detection Technology and Optimize Cancer Therapy Monitoring and Treatment
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 1 Feb 2022
BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 7 Oct 2021
SAGA Diagnostics appoints Peter Collins as Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 28 Jul 2021
Strata Oncology Completes $90 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 May 2020
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 12 Mar 2020
AbbVie Receives European Commission Approval of VENCLYXTO(R) Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2020
Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jan 2020
AbbVie Receives Positive CHMP Opinion for VENCLYXTO(R) as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Dec 2019
ArcherDX Announces Close of $55 Million Series C Financing
Diagnostics Venture Capital
 HSMN NewsFeed - 5 Mar 2019
ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth
Diagnostics Personnel
 HSMN NewsFeed - 22 Jan 2019
European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Nov 2018
AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Sep 2018
Genoptix Launches FDA-Authorized BCR-ABL MRDx(R) TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna(R) (nilotinib)
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Jun 2018
Thermo Fisher Scientific Expands Oncomine Immuno-Oncology Assay Portfolio
Diagnostics Product Launch
 HSMN NewsFeed - 15 Jun 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 May 2016
Decipher Prostate Cancer Test Guides Timing of Postoperative Radiotherapy
Diagnostics Devices Oncology
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Amgen's BLINCYTO(R) (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Nov 2015
Vaccinogen Promotes Peter Morsing, Ph.D. to Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jun 2015
Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jul 2013
Sequenta Completes $20 Million Series C Financing
Diagnostics Oncology Venture Capital Personnel
 HSMN NewsFeed - 16 Oct 2012
Clinical Study Validates Sequenta’s LymphoSIGHT(TM) Platform as More Sensitive Alternative to Flow Cytometry for Cancer Detection
Diagnostics Oncology
 HSMN NewsFeed - 4 Jun 2012
Formula Pharmaceuticals Appoints Morton Collins to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Jan 2012
Amgen to Acquire Micromet
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 7 Dec 2011
Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 5 Dec 2011
Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Jun 2011
Micromet Appoints Ulrich Grau, Ph.D. Executive Vice President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Jul 2009
EpiCept Initiates Post-Approval Clinical Study with Ceplene(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Oct 2008
EpiCept Receives Ceplene(R) Marketing Approval in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jul 2008
Ceplene(R) Receives Positive European Opinion for Approval From CHMP
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Oct 2007
Data from Investigator-Sponsored Trial of Oncophage(R) Cancer Vaccine in Glioma Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2007
Xenomics Announces Agreement with Ipsogen for Diagnostic Assays of Leukemia
Diagnostics Oncology Licensing
 HSMN NewsFeed - 11 Jul 2007
Geron Initiates Clinical Trial of Telomerase Cancer Vaccine in Patients with Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2007
FDA Clears BioView Duet(TM) System for Automated FISH Scanning of Breast Cancer Tissue Specimens
Diagnostics Oncology FDA
 HSMN NewsFeed - 14 Dec 2006
HER2/neu Vaccine Results Spurs Phase III Planning by Apthera, Inc.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
Final Data From Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jul 2006
FDA Grants Intracel Special Protocol Assessment (SPA) for Confirmatory, Pivotal Phase III Study of OncoVAX(R) Colon Cancer Vaccine
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 May 2006
Genzyme Releases Two New Molecular Tests for Acute Myelogenous Leukemia
Diagnostics Oncology
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
minimal residual disease
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.